Bioeq AG is a Swiss biopharmaceutical joint venture of Polpharma Biologics Group and Formycon AG, based in Zug, Switzerland. The company is engaged in the licensing, development, and commercialisation of its biosimilar ranibizumab, a successor to the successful branded biopharmaceutical Lucentis. Bioeq AG focuses on providing high-quality biopharmaceutical products that meet the evolving needs of the pharmaceutical industry.

Services include:
– Licensing of biosimilars
– Development of biopharmaceutical products
– Commercialisation of biosimilars
– Regulatory affairs support
– Quality assurance and control

With a commitment to advancing biopharmaceutical innovation, Bioeq AG plays a vital role in the pharmaceutical industry. For more information, please visit bioeq.ch.